CN106103462A - 台勾霉素b的新型多晶型物和新型固态 - Google Patents

台勾霉素b的新型多晶型物和新型固态 Download PDF

Info

Publication number
CN106103462A
CN106103462A CN201580013984.XA CN201580013984A CN106103462A CN 106103462 A CN106103462 A CN 106103462A CN 201580013984 A CN201580013984 A CN 201580013984A CN 106103462 A CN106103462 A CN 106103462A
Authority
CN
China
Prior art keywords
crystalline solvate
tiacumicin
xrpd
crystalline
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580013984.XA
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·克卢格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xellia Pharmaceuticals ApS
Original Assignee
Xellia Pharmaceuticals ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals ApS filed Critical Xellia Pharmaceuticals ApS
Publication of CN106103462A publication Critical patent/CN106103462A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CN201580013984.XA 2014-03-18 2015-03-17 台勾霉素b的新型多晶型物和新型固态 Pending CN106103462A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461954715P 2014-03-18 2014-03-18
US61/954,715 2014-03-18
US201462020570P 2014-07-03 2014-07-03
US62/020,570 2014-07-03
PCT/EP2015/055531 WO2015140153A1 (en) 2014-03-18 2015-03-17 New polymorphs and new solid states of tiacumicin b

Publications (1)

Publication Number Publication Date
CN106103462A true CN106103462A (zh) 2016-11-09

Family

ID=52697399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580013984.XA Pending CN106103462A (zh) 2014-03-18 2015-03-17 台勾霉素b的新型多晶型物和新型固态

Country Status (17)

Country Link
US (1) US10227371B2 (https=)
EP (1) EP3119793B1 (https=)
JP (1) JP2017507994A (https=)
KR (1) KR20160134719A (https=)
CN (1) CN106103462A (https=)
AU (1) AU2015233583B2 (https=)
BR (1) BR112016021542B1 (https=)
CA (1) CA2940902C (https=)
DK (1) DK3119793T3 (https=)
ES (1) ES2668351T3 (https=)
HR (1) HRP20180668T1 (https=)
HU (1) HUE038426T2 (https=)
IL (2) IL247726A0 (https=)
PL (1) PL3119793T3 (https=)
PT (1) PT3119793T (https=)
SI (1) SI3119793T1 (https=)
WO (1) WO2015140153A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108727387A (zh) * 2018-07-25 2018-11-02 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738A (zh) * 2018-08-29 2018-12-21 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
CN114224899A (zh) * 2020-09-09 2022-03-25 首都医科大学附属北京胸科医院 非达霉素用于制备抑制脓肿分枝杆菌活性的产品

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091554A1 (en) * 2007-01-22 2008-07-31 Optimer Pharmaceuticals, Inc. Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
WO2013170142A1 (en) * 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
WO2004014295A2 (en) 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
CN102614207B (zh) * 2005-01-31 2016-01-13 默克夏普&多梅有限公司 18元环大环化合物及其类似物
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
ITMI20120560A1 (it) 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
US8722863B2 (en) 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091554A1 (en) * 2007-01-22 2008-07-31 Optimer Pharmaceuticals, Inc. Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
WO2013170142A1 (en) * 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108727387A (zh) * 2018-07-25 2018-11-02 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738A (zh) * 2018-08-29 2018-12-21 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
CN114224899A (zh) * 2020-09-09 2022-03-25 首都医科大学附属北京胸科医院 非达霉素用于制备抑制脓肿分枝杆菌活性的产品
CN114224899B (zh) * 2020-09-09 2024-04-26 首都医科大学附属北京胸科医院 非达霉素用于制备抑制脓肿分枝杆菌活性的产品

Also Published As

Publication number Publication date
PL3119793T3 (pl) 2018-07-31
BR112016021542A2 (https=) 2017-08-15
US10227371B2 (en) 2019-03-12
PT3119793T (pt) 2018-05-10
SI3119793T1 (en) 2018-06-29
EP3119793A1 (en) 2017-01-25
DK3119793T3 (en) 2018-05-22
BR112016021542B1 (pt) 2023-01-31
KR20160134719A (ko) 2016-11-23
AU2015233583B2 (en) 2019-04-11
IL265180B (en) 2022-01-01
US20170081355A1 (en) 2017-03-23
HUE038426T2 (hu) 2018-10-29
WO2015140153A1 (en) 2015-09-24
IL265180A (en) 2019-05-30
CA2940902C (en) 2022-10-25
HRP20180668T1 (hr) 2018-06-15
CA2940902A1 (en) 2015-09-24
ES2668351T3 (es) 2018-05-17
EP3119793B1 (en) 2018-03-14
JP2017507994A (ja) 2017-03-23
IL247726A0 (en) 2016-11-30
AU2015233583A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
US10738038B2 (en) Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US10035802B2 (en) Solid state forms of ibrutinib
CN107400134B (zh) 嘌呤衍生物的结晶形式
US7759481B2 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
JP2026000991A (ja) 医薬組成物を製造する方法
CN106103462A (zh) 台勾霉素b的新型多晶型物和新型固态
WO2018196860A1 (zh) 羧酸铵盐化合物、其晶型、无定形物及其制备方法
CN104478815A (zh) 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的多种盐、它们的晶型及其制备方法
TWI707851B (zh) 哌嗪化合物的新穎結晶
US20200283381A1 (en) Solid state forms of elafibranor
WO2018001335A1 (zh) Nbi-98854的晶型及其制备方法和用途
CN113149998B (zh) 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
WO2017016512A1 (zh) 马赛替尼甲磺酸盐的新晶型及其制备方法
CN105859748A (zh) 多环化合物钠盐及其多晶型、制备方法及应用
JP2006328054A (ja) ２’−（４’−エチルベンジル）フェニル５−チオ−β−Ｄ−グルコピラノシドのＣ型結晶及びその製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161109